


# Seeking better treatment for ALS, Lou Gehrig's disease

October 29 2019

---



TDP-43 protein builds up in motor cortex and spinal cord of ALS patients, causing the nerves to die. The top three panels show nerve cells of ALS patients with extensive TDP-43 pathology in the motor cortex. Other ALS patients show little to no TDP-43 pathology, and look more like controls. Credit: Gale Hammell lab/CSHL, 2019

There is currently no cure for amyotrophic lateral sclerosis (ALS). But

new research could open up avenues for better diagnosis and more effective treatment.


The study, led by Cold Spring Harbor Laboratory Associate Professor Molly Gale Hammell, analyzed the role proteins called TDP-43 play in ALS, also known as Lou Gehrig's disease. In ALS, those proteins collect in nerve [cells](#) in the brain and spinal cord, causing sloughs of them to die off. This sweeping effect slowly paralyzes the patients.

Hammell's lab, working closely with researchers from other leading institutions, recently published the findings in *Cell Reports*.

Hammell's team tried to determine whether there were different types of ALS patients by studying the functions of the TDP-43 protein and its links to retrotransposons, also known as "[jumping genes](#)," an important part of this genetic puzzle. The [genes](#) can randomly move from one spot of a chromosome to another. They can also alter gene expression, a process in which the instructions from DNA are translated into functional activities in the cell.

TDP-43 is one of the proteins that keep jumping genes silent. But when TDP-43 accumulates in clumps or aggregates in the [nerve cells](#) of ALS patients, it fails to silence the jumping genes. Hammell's group found these telltale signs of TDP-43 pathology, or abnormal characteristics, and elevated transposons in some ALS patient samples.

Three molecular subtypes of Amyotrophic Lateral Sclerosis (ALS)



The different subtypes of ALS and the connection between TDP-43 pathology and jumping genes. Credit: Gale Hammell lab/CSHL, 2019

"These jumping genes are telling us about patients who have TDP-43 pathology," Hammell said. "We really don't know why one patient would

have one set of symptoms versus another, and we're trying to answer that question."

To find some of those answers, the team studied gene expression patterns in the brain tissues of post-mortem patients with and without TDP-43 pathology. They saw there was a de-silencing of jumping genes for the subset of patients with the most extensive TDP-43 pathology.

The team now wants to confirm whether the jumping genes actually contribute to the toxicity of cells in ALS patients. The team speculates that high levels of these jumping genes might mimic a viral pathogen or other infection in the tissues. If so, researchers may be able to directly target those genes with antiviral agents or other therapies.

"That's one of the things we're really excited about as a possibility," Hammell said. "Going forward, we want to understand whether transposons are causing the disease, and whether they're involved in other diseases that also tend to have TDP-43 aggregates, like frontotemporal dementia and some subset of Alzheimer's."

Provided by Cold Spring Harbor Laboratory

Citation: Seeking better treatment for ALS, Lou Gehrig's disease (2019, October 29) retrieved 23 April 2024 from

<https://medicalxpress.com/news/2019-10-treatment-als-lou-gehrig-disease.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--